Publication Date

2013

Abstract

In 2010, after regulatory review of rosiglitazone licensing, the US Food and Drug Administration ( FDA ) requested a reevaluation of cardiovascular end points in the RECORD trial.

School/Institute

Mary MacKillop Institute for Health Research

Document Type

Open Access Journal Article

Access Rights

Open Access

Notes

© 2013, The Authors. Published by Mosby, Inc. Open access under CC BY-NC-ND license

Included in

Cardiology Commons

Share

COinS